Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
192 USD | +0.32% | +5.86% | -11.49% |
Jun. 06 | Transcript : Insulet Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM | |
May. 30 | Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 62.3 and 50.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.49% | 13.45B | B- | ||
-2.34% | 187B | C+ | ||
+0.92% | 109B | C | ||
-1.77% | 69.22B | A | ||
-6.06% | 46.36B | B- | ||
+14.21% | 46.19B | B- | ||
+8.48% | 42.44B | B+ | ||
+19.03% | 30.84B | B | ||
+19.69% | 25.73B | A- | ||
-9.16% | 23.3B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PODD Stock
- Ratings Insulet Corporation